A new treatment has been approved for pancreatic adenocarcinoma, a common form of pancreatic cancer. This approval came ahead of schedule. The treatment is administered as a daily tablet and works by targeting a protein involved in tumor growth.

In clinical trials, this treatment showed significant improvement in overall survival rates for patients with a specific type of pancreatic cancer. The results of these trials are notable, with a substantial increase in median survival time.

Further information about this treatment and its effects can be found through additional reporting on the topic, including details about the clinical trials and the approval process.